<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02569762</url>
  </required_header>
  <id_info>
    <org_study_id>B2015:069</org_study_id>
    <nct_id>NCT02569762</nct_id>
  </id_info>
  <brief_title>Effects of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism</brief_title>
  <official_title>Assessment of the Effect of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Objectives of this study is to determine the effect(s) of daily non-caloric artificial
      sweetener (NAS) consumption (sucralose or aspartame) on the composition of the bacteria and
      also to determine the changes in glucose metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will be 12 weeks randomized, cross-over and double blinded with 2 treatment
      intervention ( sucralose and aspartame) , there will be a run in period (4 weeks), then phase
      1 treatment period for two weeks followed by four weeks washout period then phase 2 treatment
      period(2 weeks). Healthy, normglycemic (&lt;5.6 mmol/L) males and females ( 17 total) of age
      18-45 y with a body mass index (BMI) 20-25 kg/m2 will be recruited.

      Each participants will be given the dose of sweetener aspartame or sucralose during the
      treatment phase in a double-blind procedure.

      the participant will be asked to consume the sweetener in a mixed flavoured beverage during
      each visit in the treatment phase.

      Blood and stool sample collection will take place before after the run-in period, and after
      the washout period, as well as after each two-week treatment period.

      glucose measurement: Capillary blood will be collected during each visit by registered nurse.
      Blood will be collected at fasting and at 12,30,45,60,90 and 120 minutes after the
      participants drink a glucose drink (75g glucose) for Oral glucose tolerance test.

      a food frequency questionnaire will be given to each participant in order to estimate how
      often each sweetener is consumed on a daily basis.

      Participants will also be asked to complete weekly food diaries of food and drink
      consumption.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fasting Blood Glucose</measure>
    <time_frame>0-200 mins</time_frame>
    <description>Fasting blood glucose level and 2-hour oral glucose tolerance test (OGTT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insulin, glucagon,GIP &amp; GLP-1</measure>
    <time_frame>4 times during the 12 weeks period</time_frame>
    <description>glucose homeostasis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fecal Microbiome &amp; short chain fatty acids measurements</measure>
    <time_frame>4 times during the 12 weeks period</time_frame>
    <description>to detect bacterial composition in feces and SCFA changes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <arm_group>
    <arm_group_label>Sucralose-Aspartame</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generic name: sucralose or aspartame, Dosage form: powder, Duration:seven days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aspartame-Sucralose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Generic name: aspartame or sucralose, Dosage form: powder, Duration:seven days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Sucralose-Aspartame</intervention_name>
    <description>Sucralose or aspartame</description>
    <arm_group_label>Sucralose-Aspartame</arm_group_label>
    <arm_group_label>Aspartame-Sucralose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Aspartame-Sucralose</intervention_name>
    <description>Aspartame or sucralose</description>
    <arm_group_label>Sucralose-Aspartame</arm_group_label>
    <arm_group_label>Aspartame-Sucralose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 20-25 kg/m2

          -  Fasting blood glucose (FBG) &lt; 5.7 mmol/L

          -  women with regular menstrual cycle.

        Exclusion Criteria:

          -  probiotic or antibiotic use within 6 months prior to the start of the study

          -  metabolic or gastrointestinal disorders (diabetes mellitus types 1 and 2, inflammatory
             bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, phenylketonuria)

          -  pregnant or lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James K Friel, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Richardson Centre for Functional Foods &amp; Nutraceuticals</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3T 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2015</study_first_submitted>
  <study_first_submitted_qc>October 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2015</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-Nutritive Sweeteners</keyword>
  <keyword>Artificial Sweeteners</keyword>
  <keyword>Glucose Metabolism</keyword>
  <keyword>Microbiota</keyword>
  <keyword>Dysbiosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

